RadioMedix and Thor Medical enter supply agreement for thorium-228

04 Dec 2025 08:00 CET

4.12.2025 08:00:01 CET | Thor Medical ASA | Non-regulatory press releases

OSLO and HOUSTON, December 4, 2025 - Thor Medical ASA, a leading emerging
supplier of alpha-emitters for next-generation precision cancer treatment, and
RadioMedix, Inc., a U.S. based clinical-stage biotechnology company focused on
innovative targeted radiopharmaceuticals for diagnosis, monitoring and cancer
therapy, have entered into a five-year frame agreement for the supply of
thorium-228 (Th-228). The supply of Th-228 will start in 2026, with volumes
scaling with increased production at Thor Medical's AlphaOne.

RadioMedix will use the Th-228 supplied by Thor Medical as a precursor for the
manufacturing of lead-212 (Pb-212) in its development pipeline, and to leverage
the company's RAHA-100 Pb-212 generator, designed to increase the availability
of Pb-212 for the rapidly growing radiopharmaceutical industry.

"Targeted alpha therapies hold great medical and commercial potential, and the
leading players see the importance of securing scalable supply of alpha-emitters
to maintain the strong momentum. The partnership with RadioMedix reflects our
ambition to be a preferred supplier to the innovators leading the development of
these more targeted and effective cancer treatments," says Jasper Kurth, Chief
Executive Officer of Thor Medical.

"This partnership and the reliable supply of Th-228 marks an important step for
the nuclear medicine field as we work to unlock the full potential of our
RAHA-100 bench-top generator to expand clinical-grade Pb-212 production for
radiopharmaceutical research and development. Reliable access to this critical
isotope strengthens our pipeline in radiopharmaceutical drug development and
helps accelerate the advancement of targeted alpha therapies with the potential
to improve patient outcomes," said Ebrahim S. Delpassand, M.D., Chief Executive
Officer of RadioMedix.

The agreement with RadioMedix adds to Thor Medical's growing portfolio of Th-228
supply agreements with leading radiopharmaceutical companies, globally.

About Thor Medical

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium. Its proprietary production process requires no
irradiation or use of nuclear reactors, and provides reliable, environmentally
friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical
industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange under the ticker symbol 'TRMED'.

About RadioMedix

RadioMedix, Inc. is a clinical-stage biotechnology company advancing precision
solutions in nuclear medicine with a focus on targeted radiopharmaceuticals for
the diagnosis, monitoring, and therapy of hard-to-treat cancers with high unmet
need. The Company's pipeline includes best-in-class radiopharmaceuticals for PET
imaging and radionuclide therapy, with a focus on progressing the next
generation of Targeted Alpha Therapies (TAT). To support its operations,
RadioMedix built The SPICA Center, a self-sufficient, state-of-the-art 27,000
sq. ft. facility that is leading the industry in radiopharmaceutical
manufacturing and offers full-service support for academic and industry
partners. For more information, visit https://radiomedix.com/ and follow us on
LinkedIn - https://www.linkedin.com/company/radiomedix-inc-/.

Thor Medical Contact:

Brede Ellingsæter, CFO and COO, Tel: +47 472 38 440, email:
brede.ellingseter@thormedical.com

RadioMedix Contact:

info@radiomedix.com

RadioMedix Media Contact:

LifeSci Communications

radiomedixlsc@lifescicomms.com

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18740039/6614/Download%20announce
ment%20as%20PDF.pdf

More information:
Access the news on Oslo Bors NewsWeb site

661197_Download announcement as PDF.pdf